摘要
Cancer and neurodegeneration include a group of diseases that are mechanistically distinct but may share common therapeutic targets.Autophagy is a common quality control mechanism shared by mitotic and post-mitotic cells and it can be exploited to accelerate clearance of unwanted oncogenes and reduce accumulation of toxic proteins in cancer and neurodegeneration,respectively.Tyrosine kinase inhibition is a therapeutically relevant strategy that can induce autophagy, leading to normal cell survival. This article provides insights into how tyrosine kinase inhibition is clinically used to arrest mitotic cell division and tumor growth, and may promote survival of post-mitotic neurons in neurodegeneration.
Cancer and neurodegeneration include a group of diseases that are mechanistically distinct but may share common therapeutic targets.Autophagy is a common quality control mechanism shared by mitotic and post-mitotic cells and it can be exploited to accelerate clearance of unwanted oncogenes and reduce accumulation of toxic proteins in cancer and neurodegeneration,respectively.Tyrosine kinase inhibition is a therapeutically relevant strategy that can induce autophagy, leading to normal cell survival. This article provides insights into how tyrosine kinase inhibition is clinically used to arrest mitotic cell division and tumor growth, and may promote survival of post-mitotic neurons in neurodegeneration.
基金
supported by Georgetown University funding to CEHM
